Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [14C]-CC-122 in Healthy Males
NCT02234999Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avadomide in diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and solid tumor, sponsored by Celgene Corporation. Primary endpoints: Total [14C]-radioactivity in biological matrices-Pharmacokinetics (PK) up to 12 days, Cumulative excretion of total [14C]-radioactivity in urine and feces (PK) up to 12 days and 6 more. Started Sep 2014; status: completed.
02
Drugs
avadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)multiple myeloma (MM)solid tumor
Beyond the preview
Go deeper on NCT02234999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234999.